CPhI South Korea 2016

Accelerating timelines vital to securing slice of biosimilars market, KBI

By Dan Stanton contact

- Last updated on GMT

CPhI Korea in Seoul
CPhI Korea in Seoul

Related tags: South korea

Accelerated development gives biosimilars an upper hand in gaining market share, CMO KBI Biopharma told delegates in Korea yesterday.

Short timelines can be “one of the most critical decision for a lot of companies”​ when selecting a contract manufacturing organisation (CMO) to bring their biopharmaceutical to market, Thomas Jung, VP of Business Development at KBI Biopharma told delegates attending CPhI South Korea in Seoul Tuesday.

Speed in the preclinical and clinical stages brings innovative therapies to patients sooner and brings down the high cost of drug development, but has a further advantage for biosimilar developers, he said.

“There is very intense competition in the biosimilar market and an early entry is key in helping gain market share.”

For example, Remicade (infliximab) brings in roughly $9bn a year for J&J, but the commercial opportunity is falling​ as more players look to get a slice. Furthermore, some experts have predicted​ reduced development costs and growing market confidence is driving the biosimilar space to become over-crowded.

“Companies will look for any opportunity to shorten development time without sacrificing on quality,” ​Jung continued.

Streamlining methods

KBI Biopharma has therefore invested heavily to help expedite clients’ development timelines, he continued, across all stages of development and manufacture.

This includes using an Ambr 10L mini-bioreactor system for process development which Jung said the firm has been demonstrated reproducible to scales of up to 2,000L, reducing the conventional timeline from three to four months to less than 6 weeks.

The firm also uses single-use technologies in its approach to cGMP manufacturing, citing reduced timelines between batches due to the lack of CIP and SIP (cleaning in place and sterilization in place) processes, and has 200L and 2,000L Xcellerex bioreactors installed at its Durham, North Carolina manufacturing facility.

However, there are still times when a client demands specific timelines which the CMO can’t meet, Jung said, despite the continued investments across its biopharma services.

Related news

Related products

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us

Products

View more

Webinars